Clinical research
Novartis announced that, with Incyte, it is launching a Phase III clinical trial to determine if their cancer drug Jakavi (ruxolitinib) can be used to treat COVID-19.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for April 3, 2020.
A late-stage lung cancer drug under development by OSE Immunotherapeutics met its 12-month primary endpoint for survival rates following a Step-1 analysis.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for April 2, 2020.
Keytruda (pembrolizumab) hit one of the coprimary endpoints early in the Phase III KEYNOTE-177 clinical trial for a highly mutating form of colorectal cancer.
The companies initiated a Phase II/III trial in Italy, Spain, Germany, France, Japan, Canada and Russia.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for April 1, 2020.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for March 31, 2020.
“The adjustments we have made to our studies reflect our foremost concern for the safety and well-being of study participants, clinical investigators and their site staffs, our employees and communities as we face this challenging and unpredictable operating environment,” said Warren Huff, Reata’s chief executive officer and president.
Biohaven Pharmaceutical announced positive topline data from its Phase III trial of oral rimegepant (Nurtec) for preventing migraine headaches in both episodic and chronic migraine patients.
PRESS RELEASES